Severity
Low
FDA Drug recall · Reported April 30, 2025
Superpotent Drug: Assay/potency result for hydromorphone HCl in the compounded stability lot was higher than specification..
OurPharma LLC recalled HYDROmorphone Hydrochloride 50mg/50mL (1mg/mL), packaged in a 50 mL Cassette, Rx Only, Ou… - a low-severity action.
HYDROmorphone Hydrochloride 50mg/50mL (1mg/mL), packaged in a 50 mL Cassette, Rx Only, Ou… was recalled by OurPharma LLC in April 30, 2025. Reason: Superpotent Drug: Assay/potency result for hydromorphone HCl in the compounded stability lot was higher than …. Check the official notice for the remedy. Verify recall #D-0385-2025 with the FDA Drug before acting.
The recall
OurPharma LLC issued this low-severity FDA Drug recall-Superpotent Drug: Assay/potency result for hydromorphone HCl in the compounded stability lot was higher than ….
Sourced from official FDA Drug enforcement records. Verify recall #D-0385-2025 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0385-2025) was formally reported on April 30, 2025, with the manufacturer initiating the action on April 15, 2025. It is classified under Low severity (Class III), with a current status of Terminated. OurPharma LLC is listed as the recalling firm, operating out of Fayetteville, AR. Federal records list the affected scope as 1,375 cassettes.
The documented reason for this recall is: Superpotent Drug: Assay/potency result for hydromorphone HCl in the compounded stability lot was higher than specification.. Distribution data in the federal record shows the product reached: Nationwide in the USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
1,375 cassettes
Related Recalls
6
5 from same agency
HYDROmorphone Hydrochloride 50mg/50mL (1mg/mL), packaged in a 50 mL Cassette, Rx Only, OurPharma, LLC, 2512 S. City Lake Rd., Fayetteville, AR 72701, NDC 73013-1040-01.
Superpotent Drug: Assay/potency result for hydromorphone HCl in the compounded stability lot was higher than specification..
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0385-2025 |
| Date reported | April 30, 2025 |
| Date initiated | April 15, 2025 |
| Recalling firm | OurPharma LLC |
| Firm location | Fayetteville, AR |
| Affected scope | 1,375 cassettes |
| Distribution | Nationwide in the USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported April 30, 2025. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.